| 12365688 |
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
Brian R. BLANK, Jennifer Pitzen, Gang Wang, Christos TZITZILONIS, Jie Li +8 more |
2025-07-22 |
|
| 12246008 |
4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels |
Christopher James Bungard, Helen Chen, Jason M. Cox, Liangqin Guo, Michael J. Kelly, III +9 more |
2025-03-11 |
|
| 12187746 |
C26-linked rapamycin analogs as mTOR inhibitors |
Christopher Semko, Gang Wang, G. Leslie Burnett, James Aggen, Gert Kiss +6 more |
2025-01-07 |
|
| 11814367 |
Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof |
David J. Morgans, Jr., Kevin T. Mellem, Hannah Powers, Patrick Lee, Christopher Joseph Sinz |
2023-11-14 |
|
| 11739093 |
Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors |
Brian R. BLANK, Jennifer Pitzen, Gang Wang, Christos TZITZILONIS, Jie Li +8 more |
2023-08-29 |
$24,824,000 |
| 11702411 |
Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
Jie Li, Elena S. Koltun, Adrian Liam Gill, Andreas BUCKL, Naing Aay +4 more |
2023-07-18 |
$41,034,000 |
| 11685749 |
C26-linked rapamycin analogs as mTOR inhibitors |
Christopher Semko, Gang Wang, G. Leslie Burnett, James Aggen, Gert Kiss +6 more |
2023-06-27 |
$39,904,000 |
| 11673901 |
Polycyclic compounds as allosteric SHP2 inhibitors |
Elena S. Koltun, Naing Aay, Andreas BUCKL, Kevin T. Mellem, Brian R. BLANK +7 more |
2023-06-13 |
$19,402,000 |
| 11661401 |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
Elena S. Koltun, Kevin T. Mellem, Adrian Liam Gill, Gert Kiss, Christopher Semko +3 more |
2023-05-30 |
$39,941,000 |
| 10980889 |
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors |
Jennifer Pitzen, Micah James Gliedt, G. Leslie Burnett, James Aggen, Gert Kiss +6 more |
2021-04-20 |
$48,193,000 |
| 10968210 |
Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
Thomas J. Greshock, James Mulhearn, Anthony J. Roecker, Tianying Jian, Gang Zhou +9 more |
2021-04-06 |
$229,405,000 |
| 10688082 |
Aminopyrazine compounds with A2A antagonist properties |
Junying Zheng, Michael Y. Berlin, Pauline C. Ting, Guoqing Li, Dong Xiao +2 more |
2020-06-23 |
$115,870,000 |
| 10590090 |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors |
Elena S. Koltun, Kevin T. Mellem, Adrian Liam Gill, Gert Kiss, Christopher Semko +3 more |
2020-03-17 |
$26,152,000 |
| 10519147 |
Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
Thomas J. Greshock, James Mulhearn, Liangqin Guo, Ting Zhang, Deping Wang +8 more |
2019-12-31 |
$136,403,000 |
| 10221167 |
Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
Thomas J. Greshock, James Mulhearn, Junying Zheng, Ronald Kim, Ting Zhang +6 more |
2019-03-05 |
$69,271,000 |
| 10011615 |
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties |
Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang +14 more |
2018-07-03 |
$73,356,000 |
| 9676780 |
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties |
Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang +19 more |
2017-06-13 |
$92,938,000 |
| 8569312 |
Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators |
Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier +12 more |
2013-10-29 |
$46,137,000 |
| 8476274 |
Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators |
Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier +12 more |
2013-07-02 |
$146,162,000 |
| 8383818 |
Functionally selective alpha2C adrenoreceptor agonists |
Junying Zheng, Jianhua Chao, Kevin D. McCormick, Robert G. Aslanian, Mwangi W. Mutahi +1 more |
2013-02-26 |
$57,688,000 |
| 8324213 |
Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators |
Kevin D. McCormick, Li Dong, Christopher W. Boyce, Manuel de Lera Ruiz, Salem Fevrier +12 more |
2012-12-04 |
$94,767,000 |
